Premiums in Medicare plans that cap monthly out-of-pocket insulin costs are nearly twice that of plans that don’t cap costs, according to a Kaiser Family Foundation analysis. The House was poised on Thursday (March 31) to vote on a bill to cap monthly insulin costs, but many lobbyists consider insulin cost caps a policy that appeases voters without curbing prices for even insulins, never mind other drugs. “For the subset of enhanced PDPs participating in the $35 copay insulin model,...